View ValuationTetratherix 将来の成長Future 基準チェック /26Tetratherix利益と収益がそれぞれ年間31.6%と72.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-29.2% 39.3%なると予測されています。主要情報31.6%収益成長率39.26%EPS成長率Biotechs 収益成長33.8%収益成長率72.1%将来の株主資本利益率-29.21%アナリストカバレッジLow最終更新日30 Jun 2026今後の成長に関する最新情報Major Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.Major Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.すべての更新を表示Recent updatesMajor Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.お知らせ • May 29Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million.Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 333,333 Price\Range: AUD 6お知らせ • May 28Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million.Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 6 Discount Per Security: AUD 0.36 Transaction Features: Subsequent Direct ListingMajor Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.Reported Earnings • Feb 27First half 2026 earnings released: AU$0.092 loss per share (vs AU$0.086 loss in 1H 2025)First half 2026 results: AU$0.092 loss per share (further deteriorated from AU$0.086 loss in 1H 2025). Net loss: AU$4.62m (loss widened 122% from 1H 2025). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Biotechs industry in Australia.New Risk • Jan 28New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Revenue is less than US$1m (AU$1.1m revenue, or US$737k). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (AU$8.9m net loss in 3 years).お知らせ • Jan 21Tetratherix Limited Confirms Appointment of Maurizio Vecchione as Independent Non-Executive DirectorTetratherix Limited has confirmed the appointment of Mr. Maurizio Vecchione as an independent non-executive director. Mr. Vecchione has obtained the required director identification number from the Australian Business Registry Services and has provided a consent to act as a director to the Tetratherix Board. Mr. Vecchione is the Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation and General Partner at AdAstral Funds. He is also named on multiple patents filed in the United States related to material and nano-bio-polymers. Mr. Vecchione has spent the last 30 years at the forefront of biomedicine. He has helped build nine startups and launch more than 50 commercial products spanning health technologies and material sciences. His prior experience includes being Chief Executive Officer at Arrogene Nanotechnology, CompuMED, Trestle and multiple other science companies.Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Peter Gray was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 10Tetratherix Limited, Annual General Meeting, Nov 10, 2025Tetratherix Limited, Annual General Meeting, Nov 10, 2025. Location: automic group, level 5, 126 phillip street sydney, nsw 2000, AustraliaReported Earnings • Sep 02Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: AU$0.36 loss per share (further deteriorated from AU$0.11 loss in FY 2024). Net loss: AU$9.43m (loss widened 269% from FY 2024). Revenue exceeded analyst estimates by 186%. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Biotechs industry in Australia.New Risk • Jul 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$507k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).New Risk • Jul 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$502k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).New Risk • Jul 07New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$8.4m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$8.4m). Revenue is less than US$1m (AU$777k revenue, or US$505k).お知らせ • Jun 27Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million.Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,680,000 Price\Range: AUD 2.88 Discount Per Security: AUD 0.1728業績と収益の成長予測ASX:TTX - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202821-5-3-526/30/20279-7-6-726/30/20267-8-6-9212/31/20252-12-9-7N/A9/30/20252-11-6-5N/A6/30/20251-9-3-3N/A3/31/20251-6-3-2N/A12/31/20241-3-2-2N/A9/30/20241-3-2-2N/A6/30/20241-3-3-3N/A6/30/20231-200N/A6/30/20221-2-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: TTX今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: TTX今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: TTX今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: TTXの収益 ( 72.1% ) Australian市場 ( 5.7% ) よりも速いペースで成長すると予測されています。高い収益成長: TTXの収益 ( 72.1% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TTX 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 19:48終値2026/07/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Tetratherix Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Melissa BensonBarrenjoey Markets Pty LimitedScott PowerMorgans Financial Limited
Major Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.
Major Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.
Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.
Major Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.
お知らせ • May 29Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million.Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 333,333 Price\Range: AUD 6
お知らせ • May 28Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million.Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 6 Discount Per Security: AUD 0.36 Transaction Features: Subsequent Direct Listing
Major Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.
Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.
Reported Earnings • Feb 27First half 2026 earnings released: AU$0.092 loss per share (vs AU$0.086 loss in 1H 2025)First half 2026 results: AU$0.092 loss per share (further deteriorated from AU$0.086 loss in 1H 2025). Net loss: AU$4.62m (loss widened 122% from 1H 2025). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Biotechs industry in Australia.
New Risk • Jan 28New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Revenue is less than US$1m (AU$1.1m revenue, or US$737k). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (AU$8.9m net loss in 3 years).
お知らせ • Jan 21Tetratherix Limited Confirms Appointment of Maurizio Vecchione as Independent Non-Executive DirectorTetratherix Limited has confirmed the appointment of Mr. Maurizio Vecchione as an independent non-executive director. Mr. Vecchione has obtained the required director identification number from the Australian Business Registry Services and has provided a consent to act as a director to the Tetratherix Board. Mr. Vecchione is the Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation and General Partner at AdAstral Funds. He is also named on multiple patents filed in the United States related to material and nano-bio-polymers. Mr. Vecchione has spent the last 30 years at the forefront of biomedicine. He has helped build nine startups and launch more than 50 commercial products spanning health technologies and material sciences. His prior experience includes being Chief Executive Officer at Arrogene Nanotechnology, CompuMED, Trestle and multiple other science companies.
Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Peter Gray was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 10Tetratherix Limited, Annual General Meeting, Nov 10, 2025Tetratherix Limited, Annual General Meeting, Nov 10, 2025. Location: automic group, level 5, 126 phillip street sydney, nsw 2000, Australia
Reported Earnings • Sep 02Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: AU$0.36 loss per share (further deteriorated from AU$0.11 loss in FY 2024). Net loss: AU$9.43m (loss widened 269% from FY 2024). Revenue exceeded analyst estimates by 186%. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Biotechs industry in Australia.
New Risk • Jul 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$507k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).
New Risk • Jul 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$502k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).
New Risk • Jul 07New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$8.4m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$8.4m). Revenue is less than US$1m (AU$777k revenue, or US$505k).
お知らせ • Jun 27Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million.Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,680,000 Price\Range: AUD 2.88 Discount Per Security: AUD 0.1728